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Background/introduction
Soft tissue tumors are a heterogeneous group of tumors
arising from connective tissues. These tumors may be
benign, benign but locally aggressive, or malignant. Surgery
either alone or in combination with adjuvant therapies
such as radiation or chemotherapy can potentially cure a
patient with a soft tissue tumor. The morbidity and com-
plications associated with treatment can have significant
and lasting adverse effects on limb function and quality of
life. In some situations, patients develop local recurrence of
disease and require further surgery, which can result in
further treatment-associated morbidity. We have adapted
MR guided focused ultrasound (MRgFUS) techniques to
the treatment of benign and malignant soft tissue tumors
of the extremities with the goal of safely and effectively
performing MRgFUS ablation on human subjects. This
presentation describes the use of MRgFUS for the treat-
ment of desmoid fibromatosis, arteriovenous malforma-
tions, and malignant sarcomas.
Methods
Patients were treated using an MR imaging-guided
focused ultrasound system (ExAblate 2100, InSightec, Ltd,
Tirat Carmel, Israel). Treatments were performed under
general or regional anesthesia. Patients were positioned
such that the targeted tumor was overlying the transducer,
using a gel mold for positioning and for coupling to the
transducer.
MR images were obtained to define the tumor volume
and surrounding critical structures in preparation for
therapy. The treatment planning software was utilized to
define the skin surface as well as the contour of the
tumor to be treated. Fiducial markers were placed on the
images to monitor for patient motion. Sonication plan-
ning was managed by the ExAblate software, and modi-
fied as needed by the treating physician. MR generated
thermal dose maps were used to confirm heating in the
tumor, and to monitor heat accumulation on the skin.
Post-contrast imaging was used to assess the extent of
ablation within the targeted tumor. Patients were trans-
ferred to a recovery area and monitored prior to discharge
home.
Results and conclusions
The primary purpose of this protocol is to assess MR
guided high intensity focused ultrasound as an interven-
tion for treatment of soft tissue tumors of the extremities.
For patients with benign tumors, MR imaging is used to
follow the response to treatment. For malignant tumors,
all patients proceed to standard-of-care surgical resec-
tion, and the surgical specimen serves as the standard for
comparison for the predicted ablation volume on post-
treatment contrast-enhanced imaging. Ten patients with
benign and malignant soft tissue tumors have been trea-
ted thus far, as summarized in the table. Examples of
tumor treatments are included in the figures. The average
treatment time is 4h10” ± 1h47”. The average tumor
volume was 184 ± 288 cc. Treatments required an aver-
age 96 ± 53 sonications, with an average sonication
energy of 1512 J reaching an average maximum average
temperature of 55 ± 5°C. The average non-perfused
volume as a percentage of the total tumor volume
(%NPV) was 68 ± 26%. Adverse events include injury to
skin, nerves and surrounding organs.
For malignant tumors, there may be a role for MRgFUS
in the management of local recurrences. For benign but
locally aggressive tumors such as desmoid fibromatosis,
where current standard therapies are often ineffective
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and are associated with significant morbidity, minimally
invasive treatment with MRgFUS may be an appropriate
first-line therapy.
Challenges to the utilization of MRgFUS for these
applications include patient positioning on the MRgFUS
table, coupling the targeted area to the transducer, reli-
able intra-operative treatment monitoring, and speed of
treatment for large tumors. More technical development
and evidence is needed before MRgFUS can be used
routinely for the treatment of soft tissue tumors.
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1 1 desmoid popliteal fossa 142 63
2 3 desmoid buttock and
thigh
98 74
3 2 desmoid posterior ankle 42 80
4 2 desmoid lateral knee 157 48
5 2 desmoid upper abdomen 1010 67
6 1 desmoid lateral shoulder 40 18
7 1 desmoid lateral calf 320 57
8 1 AVM lateral thigh 8 100*
9 1 AVM anterior thigh 61 100*
10 1 sarcoma medial thigh 20 97
Ghanouni et al. Journal of Therapeutic Ultrasound 2015, 3(Suppl 1):O69
http://www.jtultrasound.com/content/3/S1/O69
Page 2 of 2
